CLL and Combination Therapy
A phase II study was undertaken to examine the effectiveness of rituximab and lenalidomide in patients with chronic lymphocytic leukaemia (CLL) who had not been treated (treatment naïve).
Patients were randomised based on their age: in Arm A the median age was 57 years and in Arm B it was 70 years. The response rate in Arm A was 95% with 20% of patients achieving a complete response (CR). In Arm B, 79% of patients achieved a response and 11% were CRs. Median progression-free survival was 19 months for Arm A and 20 months for Arm B. For more information, click here.